Takeda Pharmaceutical Company Limited (BVMF:TAKP34)

Market Cap	272.30B
Revenue (ttm)	159.07B
Net Income (ttm)	1.19B
Shares Out	n/a
EPS (ttm)	0.74
PE Ratio	228.61
Forward PE	n/a
Dividend	2.82 (3.46%)
Ex-Dividend Date	Sep 29, 2025

Volume	2
Average Volume	10
Open	81.49
Previous Close	n/a
Day's Range	81.49 - 81.49
52-Week Range	70.80 - 92.01
Beta	0.04
RSI	63.37
Earnings Date	Jan 29, 2026

About BVMF:TAKP34

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1781
• Employees: 47,455
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: TAKP34

Financial Performance

In 2024, BVMF:TAKP34's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY